ACTRN12619000424101
Not yet recruiting
未知
Pilot study to assess biochemical efficacy of 2 dialysis membranes in the setting of nocturnal haemodialysis.
Monash Health, Clayton, Vic,0 sites10 target enrollmentMarch 15, 2019
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Dialysis dependent end-stage renal failure
- Sponsor
- Monash Health, Clayton, Vic,
- Enrollment
- 10
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Existing nocturnal haemodialysis patients.
Exclusion Criteria
- •Those with dialysis difficulties, such as poor Arterio\-venous access.
- •Those unwilling to consent.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 2
Phase 2 study of DS-8500aType 2 Diabetes MellitusJPRN-jRCT2080222546DAIICHISANKYO Co.,Ltd.90
Recruiting
Phase 2
Meloxicam in mobilization with Colony stimulating factor (G-CSF) will improve mobilization rates in patients undergoing mobilization for autologous stem cell transplantation.Health Condition 1: null- Autologous stem cell transplantationCTRI/2014/06/004671Investigator Initiated Study50
Recruiting
Not Applicable
A clinical study to investigate the efficacy of diuretics to the HF patients with proteinuria and edema.Heart FailureJPRN-UMIN000006212Social Insurance Yokohama Central Hospital15
Active, not recruiting
Phase 1
Essai de phase II évaluant l’effet curatif de la pravastatine chez des patients présentant une fibrose cutanée et sous-cutanée radio-induite établie - PravaCURFibrose radio-induite évolutive depuis 6 à 24 mois chez des patients traités par radiothérapie cervico-faciale pour un cancer de la sphère ORL, en guérison maintenueMedDRA version: 12.1 Level: LLT Classification code 10016642 Term: FibrosisEUCTR2009-017000-83-FRInstitut Gustave Roussy40
Active, not recruiting
Not Applicable
Phase II clinical trial exploring the activity of crizotinib in patients with advanced solid tumors induced by causal alterations of specific receptors (ALK and MET/HGF receptor tyrosine kinases) expressed by cancer sells.ocally advanced and/or metastatic malignant tumor (anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, papillary renal cell carcinoma type 1, alveolar soft part sarcoma, clear cell sarcoma or alveolar rhabdomyosarcoma) deemed incurable by conventional surgery, radiotherapy, systemic therapy or any other meansMedDRA version: 15.1Level: LLTClassification code 10065867Term: Alveolar rhabdomyosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: PTClassification code 10002227Term: Anaplastic large cell lymphoma T- and null-cell typesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: PTClassification code 10001882Term: Alveolar soft part sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-001988-52-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER582